Highly Multiplexed Spatially Resolved Proteomic and Transcriptional Profiling of the Glioblastoma Microenvironment Using Archived Formalin-Fixed Paraffin-Embedded Specimens.


Journal

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
ISSN: 1530-0285
Titre abrégé: Mod Pathol
Pays: United States
ID NLM: 8806605

Informations de publication

Date de publication:
01 2023
Historique:
received: 13 04 2022
revised: 16 09 2022
accepted: 22 09 2022
pmc-release: 01 01 2024
entrez: 14 2 2023
pubmed: 15 2 2023
medline: 17 2 2023
Statut: ppublish

Résumé

Glioblastoma is a heterogeneous tumor for which effective treatment options are limited and often insufficient. Few studies have examined the intratumoral transcriptional and proteomic heterogeneity of the glioblastoma microenvironment to characterize the spatial distribution of potential molecular and cellular therapeutic immunooncology targets. We applied an integrated multimodal approach comprised of NanoString GeoMx Digital Spatial Profiling, single-cell RNA-seq (scRNA-seq), and expert neuropathologic assessment to characterize archival formalin-fixed paraffin-embedded glioblastoma specimens. Clustering analysis and spatial cluster maps highlighted the intratumoral heterogeneity of each specimen. Mixed cell deconvolution analysis revealed that neoplastic and vascular cells were the prominent cell types throughout each specimen, with macrophages, oligodendrocyte precursors, neurons, astrocytes, and oligodendrocytes present in lower abundance and illustrated the regional distribution of the respective cellular enrichment scores. The spatial resolution of the actionable immunotherapeutic landscape showed that robust B7H3 gene and protein expression was broadly distributed throughout each specimen and identified STING and VISTA as potential targets. Lastly, we uncovered remarkable variability in VEGFA expression and discovered unanticipated associations between VEGFA, endothelial cell markers, hypoxia, and the expression of immunoregulatory genes, indicative of regionally distinct immunosuppressive microdomains. This work provides an early demonstration of the ability of an integrated panel-based spatial biology approach to characterize and quantify the intrinsic molecular heterogeneity of the glioblastoma microenvironment.

Identifiants

pubmed: 36788070
pii: S0893-3952(22)00034-5
doi: 10.1016/j.modpat.2022.100034
pmc: PMC9937641
mid: NIHMS1853325
pii:
doi:

Substances chimiques

Formaldehyde 1HG84L3525

Types de publication

Journal Article Research Support, N.I.H., Intramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

100034

Subventions

Organisme : Intramural NIH HHS
ID : ZIA BC012056
Pays : United States

Informations de copyright

Published by Elsevier Inc.

Références

Science. 2019 Mar 29;363(6434):1463-1467
pubmed: 30923225
Nat Rev Clin Oncol. 2018 May;15(5):310-324
pubmed: 29434333
Cancer Cell. 2010 Jan 19;17(1):98-110
pubmed: 20129251
Science. 2020 Aug 21;369(6506):993-999
pubmed: 32820126
Mol Cell. 2021 Apr 15;81(8):1631-1639
pubmed: 33826920
PLoS One. 2013;8(3):e57188
pubmed: 23536763
Commun Biol. 2021 Jul 23;4(1):906
pubmed: 34302042
Nat Biotechnol. 2020 May;38(5):586-599
pubmed: 32393914
Cell. 2019 Jun 13;177(7):1888-1902.e21
pubmed: 31178118
Glia. 2006 Dec;54(8):850-60
pubmed: 16981197
Nat Biotechnol. 2019 Jul;37(7):773-782
pubmed: 31061481
Nat Rev Clin Oncol. 2018 May;15(5):325-340
pubmed: 29508855
Genome Biol. 2014 Dec 03;15(12):530
pubmed: 25608559
Bioinformatics. 2019 Jul 15;35(14):i436-i445
pubmed: 31510660
Cell. 2019 Mar 7;176(6):1248-1264
pubmed: 30849371
Br J Cancer. 2014 Jul 8;111(1):149-56
pubmed: 24892449
Science. 2016 Jul 1;353(6294):78-82
pubmed: 27365449
Cell. 2020 Feb 20;180(4):764-779.e20
pubmed: 32059779
Cancers (Basel). 2020 Oct 13;12(10):
pubmed: 33066172
Kidney Int. 2022 Jan;101(1):131-136
pubmed: 34555393
Neuro Oncol. 2021 Jun 1;23(6):999-1011
pubmed: 33320196
Trends Immunol. 2021 Mar;42(3):209-227
pubmed: 33495077
Science. 2018 May 11;360(6389):660-663
pubmed: 29748285
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32169869
Database (Oxford). 2019 Jan 1;2019:
pubmed: 30951143
Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8502-7
pubmed: 8710899
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
J Exp Med. 2018 Jun 4;215(6):1507-1518
pubmed: 29789388
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
Front Immunol. 2018 May 03;9:978
pubmed: 29774034
Cancer Immunol Res. 2016 Oct;4(10):858-868
pubmed: 27549123
J Neurooncol. 2007 Jun;83(2):135-44
pubmed: 17216340
Cell Rep. 2017 Oct 31;21(5):1399-1410
pubmed: 29091775
Genome Biol. 2019 Mar 22;20(1):63
pubmed: 30902100
Proc Natl Acad Sci U S A. 2015 Jan 20;112(3):851-6
pubmed: 25561528
Elife. 2020 Jan 16;9:
pubmed: 31944177
Nat Protoc. 2018 Nov;13(11):2501-2534
pubmed: 30353172
Cell. 2013 Oct 10;155(2):462-77
pubmed: 24120142
JCI Insight. 2021 Aug 9;6(15):
pubmed: 34228647
Cancer Cell. 2017 Apr 10;31(4):501-515.e8
pubmed: 28399408
BMC Immunol. 2021 Aug 11;22(1):55
pubmed: 34380434
Front Cardiovasc Med. 2019 Nov 26;6:165
pubmed: 31850371
J Neurooncol. 1998 Nov;40(2):123-30
pubmed: 9892094
Genome Biol. 2016 Apr 27;17:75
pubmed: 27122128
Cell. 2021 Nov 24;184(24):5932-5949.e15
pubmed: 34798069
Cancer Cell. 2019 Feb 11;35(2):221-237.e8
pubmed: 30753824
Clin Cancer Res. 2021 May 15;27(10):2938-2946
pubmed: 33619171
Clin Cancer Res. 2016 Jul 15;22(14):3425-3431
pubmed: 27208063
Proc Natl Acad Sci U S A. 2015 Dec 15;112(50):15408-13
pubmed: 26607445
Clin Cancer Res. 2013 Sep 15;19(18):4951-60
pubmed: 23864165
Science. 2020 Jan 17;367(6475):
pubmed: 31949051
Nature. 2008 Oct 23;455(7216):1061-8
pubmed: 18772890
Cancer Cell. 2006 Mar;9(3):157-73
pubmed: 16530701
J Neuroimmunol. 1995 Mar;57(1-2):143-53
pubmed: 7535788
Clin Cancer Res. 2019 Apr 15;25(8):2560-2574
pubmed: 30655315
Mol Cancer. 2021 Jan 4;20(1):7
pubmed: 33397409
Sci Rep. 2020 Nov 11;10(1):19542
pubmed: 33177572
Cancer Res. 2018 May 1;78(9):2370-2382
pubmed: 29449267
Nature. 2021 Jul;595(7865):107-113
pubmed: 33915569
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
EBioMedicine. 2019 Sep;47:33-43
pubmed: 31466914
Sci Rep. 2020 Sep 2;10(1):14413
pubmed: 32879419
Mol Cancer Ther. 2022 Feb;21(2):282-293
pubmed: 34815361
Genes Cancer. 2011 Dec;2(12):1117-33
pubmed: 22866203
Genome Biol. 2017 Nov 15;18(1):220
pubmed: 29141660
Nat Commun. 2022 Jan 19;13(1):385
pubmed: 35046414
Nat Commun. 2016 Aug 30;7:12624
pubmed: 27571927
Front Immunol. 2020 May 15;11:940
pubmed: 32499786

Auteurs

Youngmi Kim (Y)

NanoString Technologies, Seattle, Washington.

Patrick Danaher (P)

NanoString Technologies, Seattle, Washington.

Patrick J Cimino (PJ)

Department of Laboratory Medicine and Pathology, Division of Neuropathology, University of Washington, Seattle, Washington; Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland.

Kyle Hurth (K)

Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, California.

Sarah Warren (S)

NanoString Technologies, Seattle, Washington.

John Glod (J)

Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

Joseph M Beechem (JM)

NanoString Technologies, Seattle, Washington.

Gabriel Zada (G)

Department of Neurosurgery, Keck School of Medicine, University of Southern California, Los Angeles, California.

Troy A McEachron (TA)

Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. Electronic address: Troy.McEachron@nih.gov.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH